Rigel Pharmaceuticals Inc. (New)

RIGL Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
RIGL Income Statement
RIGL Balance Sheet
RIGL Cash Flow
Congress Trading

Recent trades of RIGL by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
RIGL Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
RIGL Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
RIGL Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by RIGL's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $10,000 Jul 16, 2021 Issue: Health Issues
  • $20,000 Jul 16, 2021 Issue: Health Issues
Corporate Lobbying

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

  • Patent Title: Rip1 inhibitory compounds and methods for making and using the same Oct. 15, 2024
  • Patent Title: Rip1k inhibitors Jul. 23, 2024
  • Patent Title: Benzazole compounds and methods for making and using the compounds Jul. 23, 2024
  • Patent Title: Irak inhibitors and method for making and using May. 28, 2024
  • Patent Title: Ret inhibitor for use in treating cancer having a ret alteration Apr. 23, 2024
  • Patent Title: Amide compounds and method for making and using Mar. 26, 2024
  • Patent Title: Compositions and methods for inhibition of the jak pathway Nov. 28, 2023
  • Patent Title: Tyrosine kinase inhibitors Jun. 13, 2023
  • Patent Title: Rip1k inhibitors Jun. 06, 2023
  • Patent Title: Compositions and methods for inhibition of the jak pathway Jun. 06, 2023
  • Patent Title: Rip1k inhibitors Feb. 21, 2023
  • Patent Title: Heterocyclic rip1 inhibitory compounds Feb. 14, 2023
  • Patent Title: Rip1 inhibitory compounds and methods for making and using the same Jan. 31, 2023
  • Patent Title: Amide compounds and method for making and using Dec. 20, 2022
  • Patent Title: 2,4-diamino-pyrimidine compounds and method for making and using the compounds Dec. 13, 2022
  • Patent Title: Irak inhibitors and method for making and using Nov. 08, 2022
  • Patent Title: Heterocyclic rip1 kinase inhibitors Oct. 25, 2022
  • Patent Title: Rip1 inhibitory compounds and methods for making and using the same Oct. 18, 2022
  • Patent Title: Tgf-β inhibitors Oct. 11, 2022
  • Patent Title: Rip1 inhibitory compounds and methods for making and using the same Aug. 09, 2022
  • Patent Title: Rip1 inhibitory compounds and methods for making and using the same Jul. 05, 2022
  • Patent Title: Pyrazole compounds and methods for making and using the compounds Jun. 28, 2022
  • Patent Title: Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations Jun. 28, 2022
  • Patent Title: Rip1 inhibitory compounds and methods for making and using the same Jun. 28, 2022
  • Patent Title: Rip1 inhibitory compounds and methods for making and using the same Jun. 28, 2022
  • Patent Title: Rip1 inhibitory compounds and methods for making and using the same May. 17, 2022
  • Patent Title: Benzazole compounds and methods for making and using the compounds Apr. 12, 2022
  • Patent Title: Nrf2 activating compounds and uses thereof Mar. 22, 2022
  • Patent Title: Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds Jan. 25, 2022
  • Patent Title: Prodrugs of 2,4-pyrimidinediamine compounds and their uses Jan. 25, 2022
  • Patent Title: Compounds and method for treating autoimmune diseases Jan. 11, 2022
  • Patent Title: Compositions and methods for inhibition of the jak pathway Dec. 14, 2021
  • Patent Title: Compositions and methods for inhibition of the jak pathway Nov. 16, 2021
  • Patent Title: Direct ampk activators Nov. 16, 2021
  • Patent Title: Fumarate analogs and uses thereof Sep. 28, 2021
  • Patent Title: Tyrosine kinase inhibitors Sep. 07, 2021
  • Patent Title: Acvr2a-specific antibody and method of treatment of muscle atrophy Aug. 31, 2021
  • Patent Title: Kinase inhibitors and methods for making and using Jul. 13, 2021
  • Patent Title: Tgf-ß inhibitors Jun. 01, 2021
  • Patent Title: 2,4-pyrimidinediamine compounds and their uses May. 18, 2021
  • Patent Title: Rip1 inhibitory compounds and methods for making and using the same Apr. 13, 2021
  • Patent Title: Amide compounds and method for making and using Mar. 16, 2021
  • Patent Title: Irak inhibitors and method for making and using Mar. 09, 2021
  • Patent Title: Nrf2 activating compounds and uses thereof Mar. 09, 2021
  • Patent Title: Ampk-activating heterocyclic compounds and methods for using the same Mar. 09, 2021
  • Patent Title: Prodrugs of nrf2 activating compounds and uses thereof Jan. 12, 2021
  • Patent Title: 2,3-disubstituted pyridine compounds as tgf-β inhibitors and methods of use Dec. 08, 2020
  • Patent Title: Tyrosine kinase inhibitors Dec. 01, 2020
  • Patent Title: Nrf2 activating compounds and uses thereof Nov. 24, 2020
  • Patent Title: Tgf-β inhibitorc Nov. 03, 2020
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of RIGL in WallStreetBets Daily Discussion

RIGL News

Recent insights relating to RIGL

CNBC Recommendations

Recent picks made for RIGL stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in RIGL

RIGL Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view RIGL Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top